For years, the practical stance in Canadian patent law has been that pre-trial injunctive relief for patent infringement is generally unavailable. However, this position was challenged in a landmark Federal Court decision by Justice Pentney in Arysta Life Science North America, LLC and UPL Agrosolutions Canada Inc. v. AgraCity Crop & Nutrition Ltd. and NewAgco Inc., 2019 FC 530.
In this case, Arysta Life Science and UPL (collectively "Arysta") sought an interim injunction to prevent AgraCity Crop & Nutrition Ltd. and NewAgco Inc. (collectively "AgraCity") from selling and distributing a herbicide product in Canada. Arysta alleged that AgraCity’s product infringed its patent on the composition and use of flucarbazone sodium, one of three patents asserted, with the interim injunction decision focusing solely on this composition and use patent.
Justice Pentney began his analysis by referencing the Supreme Court of Canada’s adoption of the House of Lords’ American Cyanamid Co. v. Ethicon Ltd. test for interlocutory injunctions. This test requires the applicant to demonstrate: (1) a serious issue to be tried on the merits; (2) irreparable harm if the injunction is refused; and (3) that the balance of convenience favors granting the injunction.
The judge acknowledged the Federal Court’s historical reluctance to grant interim injunctions in patent cases, primarily because damages for infringement are usually calculable and the threshold for irreparable harm is high. The moving party must provide clear, convincing, and non-speculative evidence of such harm.
Addressing the element of urgency, Justice Pentney rejected AgraCity’s argument that Arysta delayed unreasonably by waiting 34 days after regulatory approval and product launch to file the injunction application. He noted that Arysta presented a substantial evidentiary record, including expert and private investigator reports, and that Arysta could not have acted before AgraCity’s product launch.
On the first element, the court found that Arysta’s patent infringement claim was not frivolous or vexatious, supported by expert evidence establishing a serious issue to be tried.
The second element—irreparable harm—was pivotal. Arysta contended that there was a substantial risk AgraCity would be unable to pay any damages awarded, constituting irreparable harm. Arysta further argued that AgraCity should be required to provide evidence demonstrating its ability to satisfy a damages award.
AgraCity countered that since Arysta was not marketing a competing granular or powdered herbicide form, damages should be limited to a royalty payment, which AgraCity claimed it could afford. Justice Pentney observed that proving a defendant’s inability to pay damages is challenging and requires strong evidence raising serious doubts about collectability.
The court found that Arysta had demonstrated serious doubts regarding AgraCity’s ability to pay damages. AgraCity’s financial disclosures were insufficient, lacking details on net revenue, income, profits, or asset availability to satisfy a judgment. The judge concluded it was reasonable to expect more substantial financial evidence from AgraCity.
Regarding the royalty damages argument, Justice Pentney noted that if damages were limited to royalties, the amount would still be substantial. He further observed that Arysta could establish damages even without currently marketing a competing product form.
On the third element—the balance of convenience—the court favored Arysta. Justice Pentney criticized AgraCity for proceeding with marketing and sales without attempting to resolve patent validity issues or seeking a license, describing this as a deliberate risk taken with full awareness of potential consequences.
This decision represents a rare example of the Federal Court granting an interim injunction in an intellectual property case, signaling that such relief remains possible when the legal and factual thresholds are met. It aligns with other recent Federal Court injunctions in trademark infringement cases, such as Reckitt Benckiser LLC v. Jamieson Laboratories Ltd. and Sleep Country Canada Inc. v. Sears Canada Inc., demonstrating the court’s willingness to act when justified.
Practitioners should note that while interim injunctions in patent cases remain exceptional, the Arysta decision underscores the importance of presenting compelling evidence on urgency, irreparable harm, and the balance of convenience. Patent owners facing infringement may find renewed hope in seeking pre-trial relief under appropriate circumstances.
The content herein is intended as a general guide and does not substitute for specialist legal advice tailored to specific situations.
Federal Court Grants Uncommon Interim Injunction in Canadian Patent Infringement Dispute The Federal Court of Canada issued a rare interim injunction in a patent infringement case involving herbicide composition patents. Justice Pentney applied the established three-part test, finding serious issues to be t... Read the full IIPLA article: https://iipla.org/news/federal-court-grants-uncommon-interim-injunction-in-canadian-patent-infringement-dispute